Sanofi Aktie 699381 / FR0000120578
89.08
CHF
-1.67
CHF
-1.84%
18:00:00
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 87.61 |
| L'Oréal SA | 9.38 |
| Government Pension Fund - Global (The) | 2.11 |
| Plan d'Epargne Entreprise Sanofi Synthelabo | 2.01 |
| Dodge & Cox | 1.98 |
| Dodge & Cox International Stock Fund | 1.41 |
| Vanguard Total International Stock Index Fund | 1.14 |
| Sanofi | 0.97 |
| Vanguard Developed Markets Index Fund | 0.66 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 104'226 | 100'409 | 99'412 | 95'442 | 91'573 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.33 | 0.36 | 0.36 | 0.40 | 0.47 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 24'579 | 28'611 | 33'703 | 30'564 | 34'026 |
| Summe Anlagevermögen | 83'516 | 84'867 | 86'676 | 91'095 | 95'996 |
| Summe Aktiva | 111'408 | 112'736 | 114'529 | 120'242 | 126'722 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 24'640 | 25'933 | 23'675 | 22'414 | 21'212 |
| Summe Fremdkapital | 52'373 | 53'628 | 51'382 | 51'211 | 51'570 |
| Summe Eigenkapital | 59'035 | 59'108 | 63'147 | 69'031 | 75'152 |
| Summe Passiva | 111'408 | 112'736 | 114'529 | 120'242 | 126'722 |
Adresse
| 46, avenue de la Grande Armée, 75017 Paris | |
| Telefon | +33 (1) 53-77-40-00 |
| Fax | +33 (1) 53-77-44-03 |
| URL | http://www.sanofi.com |
Management
|
Alexandra Roger
Head-Securities Law & Capital Markets |
|
Arnaud Delépine
Investor Relations Contact |
|
Barbara Lavernos
Independent Director |
|
Brendan OCallaghan
Executive Vice President & Head-Industrial Affairs |
|
Christophe Babule
Director |
|
Claire Terrazas
Vice President-Corporate Legal Affairs |
|
Diane D. Souza
Independent Director |
|
Dietmar P. Berger
Chief Medical Officer & Global Head-Development |
|
Eva Schäfer-Jansen
Head-Investor Relations |
|
Fabienne Lecorvaisier
Independent Director |
|
Gilles Schnepp
Independent Director |
|
Jean-Baptiste Chasseloup de Chatillon
Chief Financial Officer & Executive Vice President |
|
Josep Catlla
Head-Communication |
|
Julie van Ongevalle
Executive VP & Head-Consumer Healthcare |
|
Lise Kingo
Independent Director |
|
Natalie Bickford
Chief People Officer & Executive Vice President |
|
Nestle Frank
Global Head-Immunology Therapeutic Research Area |
|
Olivier Antoine M. Charmeil
Executive Vice President-General Medicines |
|
Patrick Kron
Independent Director |
|
Paul Hudson
Chief Executive Officer & Director |
|
Rachel Duan
Independent Non-Executive Director |
|
Raj Verma
Chief Diversity, Culture & Experience Officer |
|
Roy Papatheodorou
EVP, General Counsel & Head-Legal |
|
Serge Weinberg
Chairman |
|
Thomas C. Südhof
Independent Director |
|
William J. Sibold
EVP-Specialty Care & President-North America |
|
Wolfgang Laux
Director |
|
Yann Tran
Director |
